Alpha Cognition (ACOG) Stock Price, News & Analysis

Company Overview

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $7.35 to $8.10
• 50-Day Range: $5.49 to $7.89
• 52-Week Range: $4.50 to $11.54
• Volume: 51,971 shs
• Average Volume: 43,590 shs
• Market Capitalization: $171.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.67
• Consensus Rating: Buy

Alpha Cognition Stock Analysis - MarketRank™

Alpha Cognition scored higher than 76% of companies evaluated by MarketBeat, and ranked 131st out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Alpha Cognition has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Alpha Cognition has a consensus price target of $14.67, representing about 85.9% upside from its current price of $7.89.

Amount of Analyst Coverage

Alpha Cognition has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alpha Cognition are expected to grow in the coming year, from ($1.34) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alpha Cognition is -5.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alpha Cognition is -5.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alpha Cognition has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.88% of the float of Alpha Cognition has been sold short.

Short Interest Ratio / Days to Cover

Alpha Cognition has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Alpha Cognition has recently decreased by 1.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alpha Cognition does not currently pay a dividend.

Dividend Growth

Alpha Cognition does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Alpha Cognition has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Alpha Cognition this week, compared to 3 articles on an average week.

Company Ownership

• Score: 3.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $20,160.00 in company stock, which represents 0.0117% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Alpha Cognition insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,160.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

8.60% of the stock of Alpha Cognition is held by insiders.

Percentage Held by Institutions

Alpha Cognition has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 7/04/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACOG
• CIK: 1655923
• Web: N/A
• Phone: (858) 344-4375
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alpha Cognition: $14.67
• High Price Target: $18.00
• Low Price Target: $12.00
• Potential Upside/Downside: +85.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.67 million
• Net Margins: -232.23%
• Pretax Margin: -202.25%
• Return on Equity: -58.35%
• Return on Assets: -45.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.64
• Quick Ratio: 11.52

Sales & Book Value

• Annual Sales: $10.22 million
• Price / Sales: 16.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.88 per share
• Price / Book: 2.74

Miscellaneous

• Outstanding Shares: 21,770,000
• Free Float: 19,901,000
• Market Cap: $171.77 million
• Optionable: N/A
• Beta: 2.32